Search Within

Naiyer A Rizvi

Formats
  1. Meeting Abstract (108)
  2. Journal Article (57)
  3. Research Letter (1)
Groups
  1. Department of Medicine (112)
  2. Solid Tumor Oncology Division (112)
  3. Thoracic Oncology (97)
  4. GSK Faculty (34)
  5. Department of Pathology and Laboratory Medicine (32)
  6. Radiology, Department of (30)

More Groups

People
  1. Mark Kris (71)
  2. Christopher Azzoli (37)
  3. Vincent Miller (37)
  4. Gregory Riely (30)
  5. Lee Krug (29)
  6. Matthew Hellmann (22)

More People

Years
  1. 2019 (1)
  2. 2018 (3)
  3. 2017 (6)
  4. 2016 (7)
  5. 2015 (18)
  6. 2014 (37)

More Years

Publications
  1. Journal of Clinical Oncology (65)
  2. Journal of Thoracic Oncology (28)
  3. Clinical Cancer Research (9)
  4. Annals of Oncology (8)
  5. International Journal of Radiation Oncology, Biology, Physics (8)
  6. Cancer Chemotherapy and Pharmacology (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (65)
  2. Elsevier Inc. (40)
  3. American Association for Cancer Research (13)
  4. Wiley Blackwell (10)
  5. Oxford University Press (8)
  6. Springer (8)

More Publishers

Results (166)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1b open-label study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in subjects with advanced non-small cell lung cancer
    Meeting Abstract

    Pinder, M. C.; Rizvi, N. A.; Goldberg, S. B.; Balmanoukian, A. S.; Narwal, R.; Robbins, P. B.; D'Angelo, G.; Blake-Haskins, A.; Karakunnel, J. J.; Antonia, S. J.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase 1 study of MEDI3617, a selective angiopoietin-2 inhibitor, alone and in combination with carboplatin/paclitaxel, paclitaxel, or bevacizmab in patients with advanced solid tumors
    Meeting Abstract

    Hyman, D. M.; Rizvi, N. A.; Natale, R. B.; Armstrong, D. K.; Birrer, M. J.; Recht, L. D.; Dotan, E.; Gribbin, M. J.; McDevitt, J. T.; Tavakkoli, F.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status
    Meeting Abstract

    Gettinger, S. N.; Shepherd, F. A.; Antonia, S. J.; Brahmer, J. R.; Chow, L. Q. M.; Juergens, R. A.; Borghaei, H.; Shen, Y.; Harbison, C.; Alaparthy, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Garon, E. B.; Leighl, N. B.; Rizvi, N. A.; Blumenschein, G. R.; Balmanoukian, A. S.; Eder, J. P.; Goldman, J. W.; Hui, R. N.; Soria, J. C.; Gangadhar, T. C.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Clinicopathologic features of advanced RET fusion-positive lung cancers and outcomes in comparison to other fusion-positive lung cancers
    Meeting Abstract

    Drilon, A. E.; Hellmann, M. D.; Wang, L.; Cho, E. J.; Ladanyi, M.; Rizvi, N. A.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in "pan-negative" lung adenocarcinomas (ADC) from patients with no smoking or a light smoking (NS/LS) history
    Meeting Abstract

    Drilon, A. E.; Wang, L.; Arcila, M. E.; Cho, E. J.; Balasubramanian, S.; Greenbowe, J. R.; Ross, J. S.; Stephens, P.; Lipson, D.; Miller, V. A.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis
    Meeting Abstract

    Brahmer, J. R.; Horn, L.; Gandhi, L.; Spigel, D. R.; Antonia, S. J.; Rizvi, N. A.; Powderly, J. D.; Heist, R. S.; Carvajal, R. D.; Jackman, D. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC
    Meeting Abstract

    Brahmer, J. R.; Rizvi, N. A.; Lutzky, J.; Khleif, S.; Blake-Haskins, A.; Li, X.; Robbins, P. B.; Vasselli, J.; Ibrahim, R. A.; Antonia, S. J.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results
    Meeting Abstract

    Antonia, S. J.; Gettinger, S. N.; Chow, L. Q. M.; Juergens, R. A.; Borghaei, H.; Shen, Y.; Harbison, C.; Chen, A. C.; Ready, N.; Rizvi, N. A.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Antonia, S. J.; Brahmer, J. R.; Gettinger, S. N.; Chow, L. Q. M.; Juergens, R. A.; Shepherd, F. A.; Laurie, S. A.; Gerber, D. E.; Goldman, J. W.; Shen, Y.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save